ERBB2 and cancer: In conclusion, the combination treatment of HER2-expressing cancer cells with IR700-conjugated trastuzumab and pertuzumab enhanced HER2-specific IR700 fluorescence accumulation both in vitro and in vivo, resulting in a strong phototherapeutic effect upon NIR light irradiation.